Search results for "Resistant tuberculosis"

showing 9 items of 9 documents

Drug Susceptibility Patterns in MDR-TB Patients: Challenges for Future Regimen Design. A Cross-Sectional Study

2015

Globally, there is substantial concern regarding the challenges of treating complex drug resistance patterns in multidrug resistant tuberculosis cases. Utilising data from three different settings (Estonia, Latvia, Romania) we sought to contrast drug susceptibility profiles for multidrug resistant tuberculosis cases, highlight the difficulties in designing universal regimen, and inform future regimen selection. Demographic and microbiological surveillance data for multidrug resistant tuberculosis cases from 2004-13 were analysed. High levels of additional resistance to currently recommended second line drugs were seen in all settings, with extensive variability between countries. Accurate d…

COUNTRIESEstoniaMaleDrug Resistance Multiple Bacterial/drug effectsFluoroquinolones/pharmacologyGeneral Science & TechnologyAntitubercular Agents/therapeutic useRomania/epidemiologyAntitubercular Agentslcsh:MedicineDrug Resistance Multiple BacterialMD MultidisciplinaryTuberculosis Multidrug-ResistantHumansMULTIDRUG-RESISTANT TUBERCULOSISlcsh:ScienceLatvia/epidemiologyDemographyScience & TechnologyRomanialcsh:REstonia/epidemiologyLatviaMultidisciplinary SciencesCross-Sectional StudiesScience & Technology - Other Topicslcsh:QFemaleTuberculosis Multidrug-Resistant/drug therapyResearch ArticleFluoroquinolonesPLoS ONE
researchProduct

Are moxifloxacin and levofloxacin equally effective to treat XDR tuberculosis?

2017

International audience; Background: Moxifloxacin retains partial activity against some fluoroquinolone-resistant mutants of Mycobacterium tuberculosis. Levofloxacin is presumed to be as active as moxifloxacin against drug-susceptible tuberculosis and to have a better safety profile.Objectives: To compare the in vivo activity of levofloxacin and moxifloxacin against M. tuberculosis strains with various levels of fluoroquinolone resistance.Methods: BALB/c mice were intravenously infected with 106M. tuberculosis H37Rv and three isogenic mutants: GyrA A90V, GyrB E540A and GyrB A543V. Treatment with 50 or 100 mg/kg levofloxacin and 60 or 66 mg/kg moxifloxacin was given orally every 6 h, for 4 we…

0301 basic medicineMicrobiology (medical)Tuberculosis[SDV.SP.MED] Life Sciences [q-bio]/Pharmaceutical sciences/MedicationmiceExtensively Drug-Resistant Tuberculosis030106 microbiologyMicrobial Sensitivity TestsMicrobiologyMycobacterium tuberculosis03 medical and health sciences0302 clinical medicine[SDV.SP.MED]Life Sciences [q-bio]/Pharmaceutical sciences/MedicationLevofloxacinMoxifloxacinIn vivo[SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseasesmedicineAnimalsPharmacology (medical)heterocyclic compounds030212 general & internal medicinePharmacologyMice Inbred BALB ClevofloxacinbiologyChemistry[ SDV.SP.MED ] Life Sciences [q-bio]/Pharmaceutical sciences/MedicationExtensively drug-resistant tuberculosisMycobacterium tuberculosisbiochemical phenomena metabolism and nutritionmedicine.diseasebiology.organism_classificationbacterial infections and mycosesFluoroquinolone resistanceAnti-Bacterial Agents3. Good health[ SDV.MHEP.MI ] Life Sciences [q-bio]/Human health and pathology/Infectious diseasesDisease Models AnimalSafety profileTreatment OutcomeInfectious Diseasestuberculosis[SDV.MHEP.MI] Life Sciences [q-bio]/Human health and pathology/Infectious diseasesbacteriamoxifloxacinFluoroquinolonesmedicine.drug
researchProduct

Decreased Time to Treatment Initiation for Multidrug-Resistant Tuberculosis Patients after Use of Xpert MTB/RIF Test, Latvia

2016

This test decreased time to treatment initiation by 66%–84%.

0301 basic medicineOncologyMaleEpidemiologylcsh:Medicine0302 clinical medicine1108 Medical MicrobiologyTuberculosis Multidrug-Resistant030212 general & internal medicinebacteriaDecreased Time to Treatment Initiation for Multidrug-Resistant Tuberculosis Patients after Use of Xpert MTB/RIF Test Latviabiologytime to treatment initiationDrug Resistance MicrobialMiddle Agedmultidrug-resistant tuberculosisRifampin resistanceInfectious Diseases1117 Public Health And Health ServicesTuberculosis Multidrug-Resistant/diagnosisFemaleRifampinLife Sciences & BiomedicineMicrobiology (medical)Adultmedicine.medical_specialtyTuberculosisAdolescentpulmonary030106 microbiologyXpert MTB/RIFImmunologyTime to treatmentMicrobiologylcsh:Infectious and parasitic diseasesTime-to-TreatmentMycobacterium tuberculosismolecular diagnostics03 medical and health sciencesYoung AdultAntibiotic resistancemultidrug resistanceInternal medicinemedicineHumanslcsh:RC109-216Multivariable modelantimicrobial resistanceTuberculin testAntibiotics AntitubercularScience & Technologybusiness.industryTuberculin TestResearchlcsh:RMycobacterium tuberculosis/drug effects1103 Clinical SciencesMycobacterium tuberculosisbiology.organism_classificationmedicine.diseaseAntibiotics Antitubercular/pharmacologyLatviatuberculosis and other mycobacteriaMultiple drug resistanceMODELTuberculin Test/methodsbusinessRifampin/pharmacologyMDR TB
researchProduct

Quantifying transmission fitness costs of multi-drug resistant tuberculosis.

2021

As multi-drug resistant tuberculosis (MDR-TB) continues to spread, investigating the transmission potential of different drug-resistant strains becomes an ever more pressing topic in public health. While phylogenetic and transmission tree inferences provide valuable insight into possible transmission chains, phylodynamic inference combines evolutionary and epidemiological analyses to estimate the parameters of the underlying epidemiological processes, allowing us to describe the overall dynamics of disease spread in the population. In this study, we introduce an approach to Mycobacterium tuberculosis (M. tuberculosis) phylodynamic analysis employing an existing computationally efficient mod…

EpidemiologyComputer scienceAntibiotic resistance030231 tropical medicinePopulationAntitubercular AgentsInferenceInfectious and parasitic diseasesRC109-216Drug resistanceComputational biologyMicrobial Sensitivity TestsMicrobiologylaw.inventionMycobacterium tuberculosis03 medical and health sciencesMulti-type birth–death model0302 clinical medicinelawVirologyMulti-type birth-death modelTuberculosis Multidrug-ResistantmedicineHumans030212 general & internal medicineWhole genome M. tuberculosiseducationEpidemicsPhylogenyeducation.field_of_studybiologyPhylogenetic treeMulti-drug-resistant tuberculosisPublic Health Environmental and Occupational HealthAntibiotic resistance; Multi-type birth–death model; Phylodynamics; Whole genome M. tuberculosisMycobacterium tuberculosismedicine.diseasebiology.organism_classificationPhylodynamics614: Public Health und GesundheitsförderungInfectious DiseasesViral phylodynamicsTransmission (mechanics)ParasitologyEpidemics
researchProduct

Trend in rifampicin-, multidrug- and extensively drug-resistant tuberculosis in Italy, 2009-2016

2018

In Italy, rifampicin-resistant and MDR-TB were high in foreign-born persons, but decreased from 2009 to 2016

0301 basic medicinePulmonary and Respiratory MedicineExtensively Drug-Resistant TuberculosisAntitubercular AgentsEmigrants and ImmigrantsAntitubercular Agents; Emigrants and Immigrants; Extensively Drug-Resistant Tuberculosis; Humans; Italy; Mycobacterium tuberculosis; Rifampin; Tuberculosis Multidrug-ResistantMycobacterium tuberculosis03 medical and health sciences0302 clinical medicineTuberculosis Multidrug-Resistantpolycyclic compoundsmedicineTuberculosisHumansbiologybusiness.industryExtensively drug-resistant tuberculosisMycobacterium tuberculosisMultidrug-Resistantmedicine.diseasebiology.organism_classificationVirology030104 developmental biology030228 respiratory systemItalyRifampinbusinessRifampicinmedicine.drug
researchProduct

Outbreak of multi-resistant Corynebacterium striatum infection in an Italian general intensive care unit.

2007

Microbiology (medical)AdultMaleSTRAINmedicine.medical_specialtyAdolescentNOSOCOMIAL PATHOGENCorynebacteriumlaw.inventionDisease OutbreakslawDrug Resistance Multiple BacterialRNA Ribosomal 16SmedicineHumansIntensive care medicineAgedAged 80 and overCross InfectionCorynebacterium Infectionsbusiness.industryNOSOCOMIAL PATHOGEN; STRAINOutbreakGeneral MedicineMiddle AgedIntensive care unitResistant tuberculosisCorynebacterium striatumIntensive Care UnitsInfectious DiseasesItalyFemalebusinessThe Journal of hospital infection
researchProduct

Reference set of Mycobacterium tuberculosis clinical strains: A tool for research and product development

2018

TheMycobacterium tuberculosiscomplex (MTBC) causes tuberculosis (TB) in humans and various other mammals. The human-adapted members of the MTBC comprise seven phylogenetic lineages that differ in their geographical distribution. There is growing evidence that this phylogenetic diversity modulates the outcome of TB infection and disease. For decades, TB research and development has focused on the two canonical MTBC reference strains H37Rv and Erdman, both of which belong to Lineage 4. Relying on only a few laboratory-adapted strains can be misleading as study results might not be directly transferrable to clinical settings where patients are infected with a diverse array of strains, includin…

Bacterial DiseasesResearch FacilitiesExtensively Drug-Resistant TuberculosisLineage (evolution)DiseaseAnimal PhylogeneticsMedicine and Health SciencesPhylogenyData Management0303 health sciencesGeographyPhylogenetic treeStrain (biology)QRGenomics3. Good healthActinobacteriaPhylogeneticsPhylogeographyInfectious DiseasesBiogeographyMycobacterium tuberculosis complexMedicineResearch LaboratoriesResearch ArticleComputer and Information SciencesTuberculosisTuberculosiScienceBiologyResearch and Analysis MethodsMycobacterium tuberculosis03 medical and health sciencesGenomic MedicineGeneticsmedicineTuberculosisHumansEvolutionary SystematicsTaxonomy030304 developmental biologyEvolutionary BiologyPopulation BiologyBacteria030306 microbiologyEcology and Environmental SciencesOrganismsBiology and Life SciencesGenetic VariationMycobacterium tuberculosisTropical Diseasesbiology.organism_classificationmedicine.diseaseGenòmicaPhylogenetic diversityEvolutionary biologyEarth SciencesZoologyPopulation Genetics
researchProduct

In vitro evaluation of poloxamer in situ forming gels for bedaquiline fumarate salt and pharmacokinetics following intramuscular injection in rats

2019

Graphical abstract

In situPO Propylene oxideIV IntravenousP338 Poloxamer 338lcsh:RS1-441Pharmaceutical Sciencechemistry.chemical_compoundn Sample sizeSD Standard deviationIM Intramuscularchemistry.chemical_classificationC0 Analyte plasma concentration at time zeroDoE Design of experimentsUV UltravioletPharmacology. TherapyK2.EDTA Potassium ethylenediaminetetraacetic acidLC–MS/MS Liquid chromatography-tandem mass spectrometryH&E Hematoxylin and eosintmax Sampling time to reach the maximum observed analyte plasma concentrationIn situ forming gelsCMC Critical micellar concentrationCmax Maximum observed analyte plasma concentrationIntramuscular injectionDN Dose normalizedGPT Gel point temperaturePLGA Poly-(DL-lactic-co-glycolic acid)TFA Trifluoroacetic acidCAN AcetonitrileATP Adenosine 5′ triphosphateSalt (chemistry)Polyethylene glycolPoloxamerArticlelcsh:Pharmacy and materia medicaPharmacokineticsIn vivoUHPLC Ultra-high performance liquid chromatographyPharmacokineticsAUClast Area under the analyte concentration versus time curve from time zero to the time of the last measurable (non-below quantification level) concentrationEO Ethylene oxideNMP N-methyl-2-pyrrolidoneComputingMethodologies_COMPUTERGRAPHICSAUC∞ Area under the analyte concentration vs time curve from time zero to infinite timeP407 Poloxamer 407In vitro releasePoloxamerCMT Critical micellar temperatureGel erosionIn vitrot1/2 Apparent terminal elimination half-lifechemistryMDR-TB Multi-drug resistant tuberculosisAUC80h Area under the analyte concentration versus time curve from time zero to 80 htlast Sampling time until the last measurable (non-below quantification level) analyte plasma concentrationMRM Multiple reaction monitoringNuclear chemistrySustained releaseInternational Journal of Pharmaceutics: X
researchProduct

2015

Globally, there is substantial concern regarding the challenges of treating complex drug resistance patterns in multidrug resistant tuberculosis cases. Utilising data from three different settings (Estonia, Latvia, Romania) we sought to contrast drug susceptibility profiles for multidrug resistant tuberculosis cases, highlight the difficulties in designing universal regimen, and inform future regimen selection. Demographic and microbiological surveillance data for multidrug resistant tuberculosis cases from 2004-13 were analysed. High levels of additional resistance to currently recommended second line drugs were seen in all settings, with extensive variability between countries. Accurate d…

medicine.medical_specialtyMultidisciplinaryTuberculosisCross-sectional studybusiness.industryMulti-drug-resistant tuberculosisExtensively drug-resistant tuberculosisDrug resistancemedicine.diseaseMultiple drug resistanceRegimenPharmacotherapymedicineIntensive care medicinebusinessPLOS ONE
researchProduct